Last reviewed · How we verify
Excedrin Extra Strength Pain Reliever (NSAID)
Excedrin Extra Strength Pain Reliever is a nonsteroidal anti-inflammatory drug (NSAID) developed by Haleon US Holdings, targeting cyclooxygenase. It is a small molecule modality, approved by the FDA in 2004 for various pain conditions, including headache, arthritis, and menstrual cramps. The commercial status of Excedrin Extra Strength Pain Reliever is owned by Haleon US Holdings, with approved indications for headache, cold, arthritis, muscular aches, toothache, premenstrual cramps, and menstrual cramps. Key safety considerations include potential gastrointestinal and cardiovascular risks. Excedrin Extra Strength Pain Reliever is a widely used over-the-counter medication.
At a glance
| Generic name | NSAID |
|---|---|
| Also known as | non-steroidal anti-inflammatory drugs, Isolated non-steroid anti-inflammatory group, ibuprofen, CaiFen, Meloxicam/Mobic (NDC 68382-000-01; manufacturer: Zydus; encapsulated in size AA |
| Sponsor | Haleon Us Holdings |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Target | Cyclooxygenase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- headache
- cold
- arthritis
- muscular aches
- toothache
- premenstrual cramps
- menstrual cramps
Common side effects
Key clinical trials
- The Effects of Patient and Visit Characteristics on Health Outcomes in Knee Osteoarthritis (NA)
- Post Operative Analgesia and Patient Satisfaction
- Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (NA)
- Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis (PHASE4)
- Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
- Does the Development of the Repeated Bout Effect Depend on Oxidative Stress and Inflammation? (NA)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Excedrin Extra Strength Pain Reliever CI brief — competitive landscape report
- Excedrin Extra Strength Pain Reliever updates RSS · CI watch RSS
- Haleon Us Holdings portfolio CI